Skip to main content

Table 1 the primary characteristics of the eligible studies in more detail

From: Efficacy and safety of oral compared with intravenous tranexamic acid in reducing blood loss after primary total knee and hip arthroplasty: a meta-analysis

Studies (year) Study type Surgery Treatment regimen (Dosage of TXA) Treatment regimen (number) Treatment regimen (Age)
oral intravenous oral intravenous oral intravenous
Kayupovt, 2017 RCT THA 1950 mg/kg 1000 mg 40 43 60 55
Yuan, 2017 RCT TKA 40 mg/kg 20 mg/kg 140 140 63.2 63.7
Fillingham, 2016 RCT TKA 1950 mg 1000 mg 34 37 62 63
Irwin, 2013 RCS TKA and THA 25 mg/kg (maximum 2 g) 15 mg/kg (maximum 1.2 g) 302 2698 67.6 68.2
Zohar, 2004 RCT TKA 4000 mg 10 mg/kg for 12 h 20 20 69 73
Cao, 2018 RCT THA 2000 mg 20 mg/kg 54 54 55.7 55.7
Gortemoller, 2017 RCS TKA and THA 1950 mg 1000 mg 165 165 67 68
Luo, 2017 RCS THA 2000 mg 20 mg/kg 60 60 67.6 66.98
Wang, 2018 RCT TKA 2000 mg 20 mg/kg 60 60 63.91 66.9
  1. TXA tranexamic acid, THA total hip arthroplasty, TKA total knee arthroplasty, RCT randomized controlled trial, RCS retrospective cohort study